BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...cGMP production via different routes. PL-3994 from Palatin Technologies Inc....
...to enter Phase II testing this quarter. Palatin...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...immunomodulators Fulcrum and Theravance also announced trial starts this week, with a third therapeutic from Palatin Technologies Inc....
...acute lung injury and cytokine storm initiation, preventing progression to acute respiratory distress syndrome (ARDS). Palatin...
...BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum Therapeutics Inc. Palatin Technologies Inc. [MERGED]...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...patisiran to treat hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Licensed from Palatin Technologies Inc....
BioCentury | Jun 21, 2019
Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

...MC4R agonist will be available in September. The approval triggered a $60 million payment to Palatin Technologies Inc....
...VX-661)/ivacaftor, Tez/Iva Talzenna, talazoparib (MDV3800, bmn 673, bmn-673, lt-673) AMAG Pharmaceuticals Inc. Sio Gene Therapies Inc. Gilead Sciences Inc. Novartis AG Palatin Technologies Inc. Pfizer...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...nivolumab plus Yervoy ipilimumab Treat advanced non-small cell lung cancer (NSCLC) Phase III data 2Q19 Palatin Technologies Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...First-line NSCLC in patients with tumor mutational burden ≥10 mutations per megabase PDUFA date 5/20/19 Palatin Technologies Inc....
BioCentury | Dec 12, 2018
Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

...survived and had complete tumor regression, whereas all mice treated with C. novyi -NT died. Palatin Technologies Inc....
...U.S. to treat hypertension in patients with pheochromocytoma. Mary Romeo Demser, metyrosine (ONO-5371) PL-3994 Bausch Health Companies Inc. Johns Hopkins University Palatin Technologies Inc. Natriuretic...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Pharmaceutical Inc. (NASDAQ:OHRP) Squalamine eye drops (OHR-102) Wet AMD Ph III MAKO data Early 2018 Palatin Technologies Inc....
BioCentury | Sep 8, 2017
Company News

Fosun gains rights to bremelanotide in China and Taiwan from Palatin

...Kong and Macau, and Taiwan to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin...
...double-digit royalties. Palatin and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), which holds exclusive North American rights from Palatin...
...FDA in 1Q18 for the melanocortin 4 receptor (MC4R) agonist (see BioCentury, Jan. 20 ). Palatin Technologies Inc....
BioCentury | Jun 23, 2017
Clinical News

Egalet receives CRL for 10 and 15 mg doses of pain drug Oxaydo

Egalet Corp. (NASDAQ:EGLT) said it received a complete response letter from FDA regarding a prior approval supplement for 10 and 15 mg dose strengths of oral Oxaydo oxycodone (Aversion). FDA requested more information about the...
Items per page:
1 - 10 of 301
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...cGMP production via different routes. PL-3994 from Palatin Technologies Inc....
...to enter Phase II testing this quarter. Palatin...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...immunomodulators Fulcrum and Theravance also announced trial starts this week, with a third therapeutic from Palatin Technologies Inc....
...acute lung injury and cytokine storm initiation, preventing progression to acute respiratory distress syndrome (ARDS). Palatin...
...BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Losmapimod (DUX4 inhibitor) TD-0903 PL8177 Evelo Biosciences Inc. Theravance Biopharma Inc. Fulcrum Therapeutics Inc. Palatin Technologies Inc. [MERGED]...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...patisiran to treat hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Licensed from Palatin Technologies Inc....
BioCentury | Jun 21, 2019
Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

...MC4R agonist will be available in September. The approval triggered a $60 million payment to Palatin Technologies Inc....
...VX-661)/ivacaftor, Tez/Iva Talzenna, talazoparib (MDV3800, bmn 673, bmn-673, lt-673) AMAG Pharmaceuticals Inc. Sio Gene Therapies Inc. Gilead Sciences Inc. Novartis AG Palatin Technologies Inc. Pfizer...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...nivolumab plus Yervoy ipilimumab Treat advanced non-small cell lung cancer (NSCLC) Phase III data 2Q19 Palatin Technologies Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...First-line NSCLC in patients with tumor mutational burden ≥10 mutations per megabase PDUFA date 5/20/19 Palatin Technologies Inc....
BioCentury | Dec 12, 2018
Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

...survived and had complete tumor regression, whereas all mice treated with C. novyi -NT died. Palatin Technologies Inc....
...U.S. to treat hypertension in patients with pheochromocytoma. Mary Romeo Demser, metyrosine (ONO-5371) PL-3994 Bausch Health Companies Inc. Johns Hopkins University Palatin Technologies Inc. Natriuretic...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Pharmaceutical Inc. (NASDAQ:OHRP) Squalamine eye drops (OHR-102) Wet AMD Ph III MAKO data Early 2018 Palatin Technologies Inc....
BioCentury | Sep 8, 2017
Company News

Fosun gains rights to bremelanotide in China and Taiwan from Palatin

...Kong and Macau, and Taiwan to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin...
...double-digit royalties. Palatin and AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), which holds exclusive North American rights from Palatin...
...FDA in 1Q18 for the melanocortin 4 receptor (MC4R) agonist (see BioCentury, Jan. 20 ). Palatin Technologies Inc....
BioCentury | Jun 23, 2017
Clinical News

Egalet receives CRL for 10 and 15 mg doses of pain drug Oxaydo

Egalet Corp. (NASDAQ:EGLT) said it received a complete response letter from FDA regarding a prior approval supplement for 10 and 15 mg dose strengths of oral Oxaydo oxycodone (Aversion). FDA requested more information about the...
Items per page:
1 - 10 of 301